Clinical Characteristics and Prognosis of Multiple Myeloma Patients with Myelofibrosis.
10.19746/j.cnki.issn.1009-2137.2022.01.023
- Author:
Lu CHENG
1
;
Li-Min SONG
2
;
Ru XUE
2
;
Yan-Ping MA
3
Author Information
1. The Second Clinical Medical College of Shanxi Medical University, Taiyuan 030001, Shanxi Province， China.
2. Department of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi Province， China.
3. Department of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi Province， China,E-mail:myanp18@163.com.
- Publication Type:Journal Article
- Keywords:
multiple myeloma;
efficacy;
pathogenesis;
prognosis;
secondary myelofibrosis
- MeSH:
Chromosome Aberrations;
Humans;
Multiple Myeloma/complications*;
Primary Myelofibrosis/complications*;
Prognosis;
Retrospective Studies
- From:
Journal of Experimental Hematology
2022;30(1):141-145
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the clinical characteristics and prognosis of multiple myeloma patients with myelofibrosis.
METHODS:The clinical data of 263 patients with multiple myeloma (including 92 patients with myelofibrosis) treated in the department of hematology of our hospital from January 1, 2016 to June 31, 2020 were collected and retrospectively analyzed, the patients were divided into combined group and uncombined group. The MM stage, MM type, genetic characteristics and therapeutic effect of the patients in combined group and uncombined group were observed, and the relationship between the curative effect and the degree of myelofibrosis change of the patients in combined group was analyzed.
RESULTS:There was no statistically difference in the MM staging and classification between multiple myeloma patients with or without myelofibrosis (P>0.05). The positive rate of FISH results of the patients in combined group was significantly higher than those in uncombined group, and was significantly correlated to 1q21 amplification, D13S319 deletion, and IgH breakage (P<0.05). After treatment, the effective rate of the patients in uncombined group was significantly higher than those in combined group, and the degree of fibrosis in the effective patients in combined group was significantly reduced.
CONCLUSION:The survival rate of the patients with multiple myeloma complicated with myelofibrosis is shorter than that of the patients without myelofibrosis, and the overall prognosis is poor.
